课题基金 / 基金详情

LIPID AND LIPOPROTEIN METABOLISM IN ATHEROSCLEROSIS (CORE A)

LIPID AND LIPOPROTEIN METABOLISM IN ATHEROSCLEROSIS (CORE A)
动脉粥样硬化中的脂质和脂蛋白代谢(核心 A)
批准号:
7717969
负责人:
Alan M Fogelman
金额:
$3.85万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-12-01 至 2008-11-30

项目摘要

项目成果

Alan M Fogelman的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In general HDL (the "good cholesterol") is inversely correlated for risk for coronary artery disease (i.e. the more HDL a person has, the less likely it is that the person will have coronary artery disease). However, while this is true for populations, in fact about 40 to 45% of all heart attacks occur in subjects with perfectly normal HDL levels. Our preliminary research has shown that HDL from normal individuals (.i.e those without known coronary artery diseas) is able to inhibit lipid oxidation and is ant-inflammatory. In contrast, we have found in this preliminary research that individuals with normal HDL-cholesterol levels who have coronary artery disease almost always have HDL that is dysfunctional. Their HDL is less able to inhibit lipid oxidation and in fact may actually promote lipid oxidation and instead of being anti-inflammatory, their HDL is pro-inflammatory.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting the Enterocyte to Prevent Vascular Inflammation
Targeting the Enterocyte to Prevent Vascular Inflammation
Targeting the Enterocyte to Prevent Vascular Inflammation
LIPID AND LIPOPROTEIN METABOLISM IN ATHEROSCLEROSIS (CORE A)
海外基金